Cargando…
Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
PURPOSE: We and others have demonstrated that MYC-amplified medulloblastoma (MB) cells are susceptible to class I histone deacetylase inhibitor (HDACi) treatment. However, single drug treatment with HDACi has shown limited clinical efficacy. We hypothesized that addition of a second compound acting...
Autores principales: | Valinciute, Gintvile, Ecker, Jonas, Selt, Florian, Hielscher, Thomas, Sigaud, Romain, Ridinger, Johannes, Thatikonda, Venu, Gatzweiler, Charlotte, Robinson, Sarah, Talbot, Julie, Bernardi, Flavia, Picard, Daniel, Blattner-Johnson, Mirjam, Schmid, Simone, Jones, David T., van Tilburg, Cornelis M., Capper, David, Kool, Marcel, Remke, Marc, Oehme, Ina, Pfister, Stefan M., Roussel, Martine F., Ayrault, Olivier, Witt, Olaf, Milde, Till |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232604/ https://www.ncbi.nlm.nih.gov/pubmed/37183219 http://dx.doi.org/10.1007/s11060-023-04319-1 |
Ejemplares similares
-
EMBR-01. CLASS I HDAC INHIBITORS AND PLK1 INHIBITORS SYNERGIZE IN MYC-AMPLIFIED MEDULLOBLASTOMA
por: Valinciute, Gintvile, et al.
Publicado: (2021) -
MBRS-19. SYNERGISM OF HDAC AND PARP INHIBITORS IN MYC-DRIVEN GROUP 3 MEDULLOBLASTOMA CELLS
por: Vollmer, Johanna, et al.
Publicado: (2020) -
Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells
por: Vollmer, Johanna, et al.
Publicado: (2023) -
LGG-03. EXPLORING THE SIGNALING NETWORK INVOLVED IN MAPK PATHWAY INHIBITION BY THE MEK INHIBITOR TRAMETINIB IN BRAF-FUSION-DRIVEN PEDIATRIC PILOCYTIC ASTROCYTOMA
por: Sigaud, Romain, et al.
Publicado: (2023) -
LGG-27. Molecular implications of mitogen-activated protein kinase pathway inhibition by the MEK inhibitor trametinib in BRAF-fusion-driven pediatric pilocytic astrocytoma
por: Sigaud, Romain, et al.
Publicado: (2022)